Prescient Therapeutics (Formerly Known As Virax Holdings Limited)
89 High Street, Kew
Suite 220, Kew Junction Tower
Melbourne
Victoria
3101
Tel: +61 3 9854 6230
Fax: +61 3 9853 5134
Website: http://www.virax.com.au/
Email: virax@virax.com.au
About Prescient Therapeutics (Formerly Known As Virax Holdings Limited)
Virax Holdings Limited, based in Melbourne, Australia is a public, listed biotechnology company engaged in the discovery and development of immunotherapeutics for the treatment of HIV/AIDS, cancer, infectious and autoimmune diseases.Virax's business strategy is to identify and in-license promising early stage bio-technologies, conduct R&D followed by early stage clinical trials to demonstrate commercial value and then to partner with major bio-pharmaceutical companies to complete clinical trials and commercialization.
AHL is their Australian Ticker!
2 articles about Prescient Therapeutics (Formerly Known As Virax Holdings Limited)
-
Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers
7/11/2019
Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.
-
Virax Holdings Limited Grants TRANSGENE Co-X-Gene(TM) Technology License for Two Immunotherapeutic Products
3/13/2007